Skip to main content

Advertisement

SpringerLink
Log in

Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance

  • Research Article
  • Published:
Tumor Biology

Abstract

This study aimed to analyze the expression, clinical significance of proto-oncogene in non small cell lung cancer (NSCLC), and the biological effect in its cell line by siRNA targeting wild-type p53-induced phosphatase 1 (Wip1). Immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) were, respectively, used to analyze Wip1 protein expression in 75 cases of NSCLC and normal tissues to study the relationship between Wip1 expression and clinical parameters. Wip1 siRNA was transiently transfected into papillary NSCLC H1299 cell by liposome-mediated method and was detected by RT-PCR and Western blot. MTT assay, cell apoptosis, and cell cycle were also conducted as to the influence of the downregulated expression of Wip1 that might be found on H1299 cells biological effect. The positive rates of Wip1 protein was 69.3 % in NSCLC tissues but 16.0 % expressed in normal tissues (P < 0.05). The relative content of Wip1 mRNA was 0.785 ± 0.062 and 0.147 ± 0.020 in NSCLC tissues and normal tissues, respectively, with significant differences between the two types (P < 0.05). There were no significant differences between Wip1 expression and sex, age, tumor size, and pathological types (P > 0.05). However, there were significant differences between Wip1 expression and lymph node metastasis, clinical stages, and tumor differentiation (P < 0.05). Individuals with positive and negative levels of Wip1 expression showed were statistically significant differences in the 5-year overall survival rate (P < 0.05). RT-PCR and Western blot showed that H1299 cell transfected Wip1 siRNA had a lower relative expressive content than normal cell (P < 0.05). MTT assay, cell apoptosis, and cell cycles demonstrated that H1299 cell transfected Wip1 siRNA had a lower survival fraction, higher cell apoptosis, more percentage of the G0/G1 phases, and lower cells in the S phases (P < 0.05). Wip1 protein and mRNA were increased in NSCLC, specifically in lymph node metastasis, clinical stages, and tumor differentiation. Wip1 may be involved in the biological processes of NSCLC cell proliferation, cell apoptosis, and cell cycle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Sculier JP. Non small cell lung cancer. Eur Respir Rev. 2013;22:33–6.

    Article  PubMed  Google Scholar 

  2. Sculier JP, Berghmans T, Meert AP. Thoracic oncology: annual review. Rev Med Brux. 2013;34:100–11.

    PubMed  Google Scholar 

  3. Fuku T, Semba S, Yutori H, Yokozaki H. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int. 2007;57:566–71.

    Article  CAS  PubMed  Google Scholar 

  4. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 2002;31:133–4.

    Article  CAS  PubMed  Google Scholar 

  5. Saito-Ohara F, Imoto I, Inoue J, Inoue J, Hosoi H, Nakagawara A, et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003;63:1876–83.

    CAS  PubMed  Google Scholar 

  6. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, et al. Economic and protein expression profiling identifies CDK6 as novel in dependent prognostic marker in medulloblastoma. J Clin Oncol. 2005;23:8853–62.

    Article  CAS  PubMed  Google Scholar 

  7. Yang DH, He JA, Li J, Ma WF, Hu XH, Xin SJ, et al. Expression of proto-oncogene Wip1 in breast cancer and its clinical significance. Natl Med J Chin. 2010;90:519–22.

    CAS  Google Scholar 

  8. Ling CH, Jiao BH, Lu SK, Guo EK, Zhang GY. The expression of proto-oncogene Wip1 in human glioblastoma multiforme and cell lines. Chin J Neuro-Oncol. 2011;9:1–6.

    Google Scholar 

  9. Ling CH, Jiao BH, Guo EK, Lu SK. Overexpression of proto-oncogene Wip1 in intracranial ependymomas association with P53. Basic Clin Med. 2011;31:430–4.

    Google Scholar 

  10. Yang DH, Zhang H, Hu XH, Xin SJ, Duan ZQ. Abnormality of p16/p38MAPK/p53/Wip1 pathway in papillary thyroid cancer and its significance. Chin J Gen Surg. 2011;20:1199–202.

    CAS  Google Scholar 

  11. Oliva TM, Berthonaud V, Chevalier A, Ducrot C, Marsolier-Kergoat MC, Mann C, et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumor suppressor kinase. Oncogene. 2007;26:1449–58.

    Article  Google Scholar 

  12. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non small cell lung cancer. Lancet. 2011;378:1727–40.

    Article  PubMed  Google Scholar 

  13. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non small cell lung cancer: recent developments. Lancet. 2013;382:709–19.

    Article  CAS  PubMed  Google Scholar 

  14. Tsim S, O'Dowd CA, Milroy R, Davidson S. Staging of non small cell lung cancer (NSCLC): a review. Respir Med. 2010;104:1767–74.

    Article  CAS  PubMed  Google Scholar 

  15. Wang P, Rao J, Yang HF, Zhao HY, Yang L. Inhibitory effects of lentivirus mediated RNA interference targeting human Wip1 gene on the proliferation of human glioma U251 cells. Chin J Exp Surg. 2010;27:76–9.

    Google Scholar 

  16. Baxter EW, Milner J. p53 Regulates LIF expression in human medulloblastoma cells. J Neurooncol. 2010;97:373–82.

    Article  CAS  PubMed  Google Scholar 

  17. Lowe JM, Cha H, Yang Q, Fornace Jr AJ. Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. J Biol Chem. 2010;285:5249–57.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Armstrong NJ, Fagotto F, Pthmann C, Rupp RA. Maternal Wnt/β-catenin signaling coactivates transcription through NF-κB binding sites during Xenopus axis formation. PLoS One. 2012;7:e36136.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Pan H, Zhou W, He W, Liu X, Ding Q, Ling L, et al. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-kappaB activity via the Notch-1 pathway. Int J Mol Med. 2012;30:337–43.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Tumor, The First Hospital of Qinhuangdao, No. 258, Wenhua Road, Haigang District, Qinhuangdao, 066000, Hebei Province, China

    Zhanzhao Fu, Guogui Sun & Tao Gu

  2. Department of Chemoradiotherapy, Tangshan People’s Hospital, Tangshan, 063000, China

    Guogui Sun

Authors
  1. Zhanzhao Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guogui Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhanzhao Fu or Guogui Sun.

Additional information

Zhanzhao Fu and Guogui Sun contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fu, Z., Sun, G. & Gu, T. Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance. Tumor Biol. 35, 2975–2981 (2014). https://doi.org/10.1007/s13277-013-1382-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1382-y

Keywords

Search

Navigation